Limits...
Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.

Lamarthée B, Malard F, Saas P, Mohty M, Gaugler B - Front Immunol (2016)

Bottom Line: Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase.Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells.Interleukin-22 (IL-22) is produced by both immune and adaptive cells and has both protective and inflammatory properties.

View Article: PubMed Central - PubMed

Affiliation: Centre de Recherche Saint Antoine, INSERM UMR 938, Paris, France; Université Pierre et Marie Curie, Paris, France.

ABSTRACT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD triggering has been investigated by several groups and resulted in the identification of new cellular and molecular effectors involved in GVHD pathogenesis. Interleukin-22 (IL-22) is produced by both immune and adaptive cells and has both protective and inflammatory properties. Its role in GVHD processes has been investigated, and the data suggest that its effect depends on the timing, the target tissue, and the origin of the producing cells (donor/host). In this review, we discuss the role of IL-22 in allo-HSCT and GVHD.

No MeSH data available.


Related in: MedlinePlus

Balance between inflammatory and protective effect of IL-22.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836046&req=5

Figure 3: Balance between inflammatory and protective effect of IL-22.

Mentions: A solid basis of data from in vitro and in vivo models is now accumulating to support IL-22s pleiotropic function. In particular, its dual pro-inflammatory and anti-inflammatory nature constitutes the largest obstacle to developing therapeutics based on this molecule (Figure 3). Therefore, further studies are required, especially in the human setting, to comprehensively explore the role of IL-22 in allo-HSCT.


Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.

Lamarthée B, Malard F, Saas P, Mohty M, Gaugler B - Front Immunol (2016)

Balance between inflammatory and protective effect of IL-22.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836046&req=5

Figure 3: Balance between inflammatory and protective effect of IL-22.
Mentions: A solid basis of data from in vitro and in vivo models is now accumulating to support IL-22s pleiotropic function. In particular, its dual pro-inflammatory and anti-inflammatory nature constitutes the largest obstacle to developing therapeutics based on this molecule (Figure 3). Therefore, further studies are required, especially in the human setting, to comprehensively explore the role of IL-22 in allo-HSCT.

Bottom Line: Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase.Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells.Interleukin-22 (IL-22) is produced by both immune and adaptive cells and has both protective and inflammatory properties.

View Article: PubMed Central - PubMed

Affiliation: Centre de Recherche Saint Antoine, INSERM UMR 938, Paris, France; Université Pierre et Marie Curie, Paris, France.

ABSTRACT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is still limited by complications, such as graft-versus-host disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that leads to the destruction of healthy host tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD triggering has been investigated by several groups and resulted in the identification of new cellular and molecular effectors involved in GVHD pathogenesis. Interleukin-22 (IL-22) is produced by both immune and adaptive cells and has both protective and inflammatory properties. Its role in GVHD processes has been investigated, and the data suggest that its effect depends on the timing, the target tissue, and the origin of the producing cells (donor/host). In this review, we discuss the role of IL-22 in allo-HSCT and GVHD.

No MeSH data available.


Related in: MedlinePlus